골다공증 검사 시장

The Global Osteoporosis Testing Market reached USD 383.5 million in 2022 and is projected to witness lucrative growth by reaching up to USD 566.8 million by 2030. The global osteoporosis testing market is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030). With mergers, acquisitions, and product launches, the global osteoporosis testing market is moderately competitive. Some of the key players in the market are GE Healthcare, DMS Imaging, Swissray, BeamMed Ltd, Hologic Inc, and others.
For instance, on January 9, 2023, GE Healthcare announced entering into an acquisition agreement with IMACTIS, an innovator in the quickly growing area of computed tomography (CT) interventional guidance over an array of care areas. IMACTIS is a company based in France that was established in 2009, it developed CT-Navigation, a universal solution providing stereotactic needle guidance.
The factors influencing the trends in the global osteoporosis testing market are technological advancements and the increasing prevalence of osteoporosis.
Osteoporosis is a disease that can worsen over time. This can cause the bone to become more porous and more prone to breaking. Dual Energy X-ray Absorptiometry, also known as a DXA or DEXA scan, is the current gold-standard method for diagnosing osteoporosis. Additionally, the growing number of incidences of osteoporosis cases is driving the global osteoporosis testing market growth.
Osteoporosis Testing Market Dynamics and Trends
Technological Advancements Lead to the Market’s Growth and are One of the Main Factors Driving the Market Growth.
A variety of technologies have been used to assess skeletal health, the most common of which is dual-energy X-ray absorptiometry (DXA), which measures the spine, hip or entire body. The skeletal health assessment has become faster and more accurate due to recent advances in imaging technology.
For instance, the Hologic, Bedford, MA-based Discovery QDR Series bone densitometer includes High-Definition Instant Vertebral Assessment (IVA), which takes a 10-second scan of the lumbar, thoracic spine to detect vertebral deformities. This allows classifying more patients as osteoporotic, even if their BMD results are borderline.
A Growing Number of Incidences of Osteoporosis Will Create Opportunities for the Market Players.
The growing number of incidents of osteoporosis is driving the growth of the osteoporosis testing market. Rapid turnaround time and lower cost of procedure over conventional methods also fuel the growth of the osteoporosis testing market. For instance, osteoporosis affects an estimated 75 million people in Europe, North America, and Japan. An increasing number of patients have been visiting for osteoporosis testing, and its growing demand exhibits lucrative growth opportunities for companies investing in this market.
Limitations Associated With Osteoporosis Testing are Factors Hindering the Market Growth.
A DXA test cannot predict who will fracture. DXA is of limited use in people with a spinal deformity or those who have had previous spinal surgery, despite its effectiveness in measuring bone density. One of the major drawbacks of DXA is that there is currently no standardization in bone and soft tissue measurements. There are significant differences in measurements obtained on instruments from the three major DXA machine manufacturers.

Moreover, high cost is also expected to hamper market growth. For instance, the cost of the DXA instrument, which is likely to exceed $100,000, accounts for the majority of the costs associated with its use. Although DXA is better suited to lab-based research rather than field testing.

Osteoporosis Testing Market Segment Analysis
The global osteoporosis testing market is segmented based on type, end user and region.
The X-ray Scan Segment Will be Dominated by Market Players During the Forecast Period.
X-ray scans accounted for the highest market stake accounting for approximately 59.7% of the osteoporosis testing market in 2022. X-ray is very helpful and crucial in the diagnosis of osteoporosis. The key X-ray finding indicative of osteoporosis is the loss of bone mass. The main loss is found in the bony trabecula rather than the cortex. The common bones observed for osteoporosis are the lumbar vertebrae, femoral neck and calcaneus.
All X-ray methods offer a bone mineral density (BMD) measure. Still, it has been illustrated that other structural outlooks of the bone are crucial in evaluating fracture risk, like elastic properties and mechanical features, which cannot be determined with densitometry techniques.
There are various techniques used for osteoporosis, including dual X-ray absorptiometry scans, quantitative computed tomography scans and morphometry. Among the commonly utilized techniques, dual X-ray absorptiometry (DXA) is currently the “gold standard” for fracture risk prediction and osteoporosis diagnosis.

Osteoporosis Testing Market Geographical Penetration
North America is the Dominating Region During the Forecast Period.
North America captured approximately 38.5% of the overall market. The most prevalent bone disease, osteoporosis, which affects roughly 10 million people in the United States alone, causes bones to become weak and prone to fractures. The disease is especially common in women, with nearly 20% of women over age 50 having osteoporosis and over half exhibiting the precursor condition of low bone mass.
Each year, osteoporosis-related fractures account for 432,000 hospital admissions and 180,000 nursing home admissions. Given the aging population in the U.S., annual direct costs from osteoporosis are expected to reach approximately $25.3 billion by 2025.
Osteoporosis Testing Market Competitive Landscape
The major global players include GE Healthcare, DMS Imaging, Swissray, BeamMed, Hologic, OSTEOSYS, Scanflex Healthcare, CompuMed, FUJIFIL, and Trivitron Healthcare among others.
COVID-19 Impact on Osteoporosis Testing Market
The COVID-19 pandemic impacted the osteoporosis testing market significantly. The COVID-19 illness and treatment adversely affected the bone health of surviving patients, affecting the market’s growth pace.
According to an article published by the National Library of Medicine in April 2022, post-acute sequela of COVID-19 can cause secondary osteoporosis. To help with the early detection and treatment of osteoporosis problems, the bone health status of patients who survived COVID-19 hospitalization is extensively examined at subsequent visits.
With the increased number of COVID-19 patients, the early detection of bone density and bone examination increased, leading to increased demand for bone densitometers.
Russia-Ukraine Impact Analysis
The conflict between Russia and Ukraine has caused a disruption of the supply chain for some of the equipment used in osteoporosis testing, increasing costs for consumers and making it more difficult for them to access the necessary testing. These factors have had a significant impact on the osteoporosis testing market.
Artificial Intelligence Impact Analysis
AI has a significant impact on the overall osteoporosis testing market as new techniques are getting developed. For instance, according to a study in radiology artificial intelligence by the Radiological Society of North America it was found that a new method that combines imaging information with AI can diagnose osteoporosis from hip X-rays.
The Geneva-based Medimaps group has also developed a spine segmentation (SpS) deep learning algorithm, which can enhance and improve the diagnosis and monitoring of osteoporosis.
Key Developments
• In September 2022, A new device for diagnosing bone fragility invented by the University Hospitals of Geneva (HUG) and the University of Geneva (UNIGE) was approved for marketing in the European Economic Area and Switzerland and licensed by the Northern Irish company ProAxsis. The device is based on a new approach to assessing bone quality via blood sampling.
• In April 2021, AMGA Foundation, in collaboration with Amgen, one of the world's leading biotechnology companies, launched its Osteoporosis Best Practices Learning Collaborative, a 12-month initiative focused on helping medical groups develop strategies to reduce fracture rates among patients with osteoporosis. This initiative is designed to provide a platform for participating organizations to improve clinical and economic outcomes through developing and implementing quality improvement projects, best practice sharing, and peer-to-peer learning.
• In November 2022, MEDIMAPS GROUP, a Swiss/Global med-tech company specializing in image processing software for assessing bone health, announced that its novel method for enhancing osteoporotic fracture risk assessment, Trabecular Bone Score (TBS iNsight), a surrogate of bone microarchitecture boosted by AI, is available on diagnostic platforms from OsteoSys. OsteoSys is the leading Bone Mineral Densitometer brand in Korea and the third-largest supplier of DXA scanning equipment worldwide.
Why Purchase the Report?
• To visualize the global osteoporosis testing market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global osteoporosis testing market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Osteoporosis Testing Market Report Would Provide Approximately 92 Tables, 108 Figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies